Tempest Reports 100% CR Rate in Ongoing REDEEM-1 Trial of TPST-2003.

Tempest Therapeutics has announced interim results from its REDEEM-1 trial of TPST-2003, a treatment for relapsed/refractory multiple myeloma. The trial achieved a 100% complete response rate among all six efficacy evaluable patients, with a favorable safety profile and no Grade >3 CRS or ICANS. The prior investigator-initiated trial reached a median progression-free survival of 23.1 months, including in patients with extramedullary disease. Tempest plans to submit a U.S. IND and initiate a U.S. registrational study in 2026.